Literature DB >> 26332853

Activation of annexin A1 signalling in renal fibroblasts exerts antifibrotic effects.

H Neymeyer1, R Labes1, V Reverte2, F Saez2, T Stroh3, C Dathe1, S Hohberger1, M Zeisberg4, G A Müller4, J Salazar2, S Bachmann1, A Paliege1,5.   

Abstract

AIM: The anti-inflammatory protein annexin A1 (AnxA1) and its formyl peptide receptor 2 (FPR2) have protective effects in organ fibrosis. Their role in chronic kidney disease (CKD) has not yet been elucidated. Our aim was to characterize the AnxA1/FPR2 system in models of renal fibrosis.
METHODS: Rats were treated with angiotensin receptor antagonist during the nephrogenic period (ARAnp) to induce late-onset hypertensive nephropathy and fibrosis. Localization and regulation of AnxA1 and FPR2 were studied by quantitative real-time PCR and double labelling immunofluorescence. Biological effects of AnxA1 were studied in cultured renal fibroblasts from AnxA1(-/-) and wild-type mice.
RESULTS: Angiotensin receptor antagonist during the nephrogenic period kidneys displayed matrix foci containing CD73(+) fibroblasts, alpha-smooth muscle actin (a-SMA)(+) myofibroblasts and CD68(+) macrophages. TGF-β and AnxA1 mRNAs were ~threefold higher than in controls. AnxA1 was localized to macrophages and fibroblasts; myofibroblasts were negative. FPR2 was localized to fibroblasts, myofibroblasts, macrophages and endothelial cells. AnxA1 and FPR2 immunoreactive signals were increased in the foci, with fibroblasts and macrophages expressing both proteins. AnxA1(-/-) fibroblasts revealed higher α-SMA (sevenfold) and collagen 1A1 (Col1A1; 144-fold) mRNA levels than controls. Treatment of murine WT fibroblasts with TGF-β (22.5 ng mL 24 h(-1)) increased mRNA levels of α-SMA (9.3-fold) and Col1A1 (fourfold). These increases were greatly attenuated upon overexpression of AnxA1 (1.5- and 1.7-fold, respectively; P < 0.05). Human fibroblasts reacted similarly when receiving the FPR2 inhibitor WRW4.
CONCLUSION: Our results demonstrate that AnxA1 and FPR2 are abundantly expressed in the renal interstitium and modulate fibroblast phenotype and extracellular matrix synthesis activity.
© 2015 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  TGF-β; extracellular matrix; formyl peptide receptor 2; myofibroblast

Mesh:

Substances:

Year:  2015        PMID: 26332853     DOI: 10.1111/apha.12586

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  15 in total

Review 1.  Annexin A1: shifting the balance towards resolution and repair.

Authors:  Giovanna Leoni; Asma Nusrat
Journal:  Biol Chem       Date:  2016-10-01       Impact factor: 3.915

Review 2.  Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets.

Authors:  Wenshan Lv; George W Booz; Yangang Wang; Fan Fan; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2017-12-08       Impact factor: 4.432

3.  Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure.

Authors:  Fadi W Adel; Aruna Rikhi; Siu-Hin Wan; Seethalakshmi R Iyer; Hrishikesh Chakraborty; Steven McNulty; W H Wilson Tang; G Michael Felker; Michael M Givertz; Horng H Chen
Journal:  J Card Fail       Date:  2020-05-27       Impact factor: 5.712

Review 4.  Annexin Animal Models-From Fundamental Principles to Translational Research.

Authors:  Thomas Grewal; Carles Rentero; Carlos Enrich; Mohamed Wahba; Carsten A Raabe; Ursula Rescher
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

5.  Heterogeneity of mast cells and expression of Annexin A1 protein in a second degree burn model with silver sulfadiazine treatment.

Authors:  Helena Ribeiro Souza; Lucas Ribeiro de Azevedo; Lucas Possebon; Sara de Souza Costa; Melina Mizusaki Iyomasa-Pilon; Sonia Maria Oliani; Ana Paula Girol
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

6.  Annexin A1 is elevated in patients with COPD and affects lung fibroblast function.

Authors:  Tianwen Lai; Yanyu Li; Zongjiong Mai; Xiaoxia Wen; Yingying Lv; Zhanqing Xie; Quanchao Lv; Min Chen; Dong Wu; Bin Wu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-05

7.  Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Valeria Pecci; Monica Carmosino; Giuseppe Procino; Alessandro Pini; Mario De Rosa; Vincenzo Pavone; Maria Svelto; Paola Bagnoli
Journal:  J Cell Mol Med       Date:  2018-11-13       Impact factor: 5.310

Review 8.  Annexin-A1: Therapeutic Potential in Microvascular Disease.

Authors:  Gareth S D Purvis; Egle Solito; Christoph Thiemermann
Journal:  Front Immunol       Date:  2019-04-30       Impact factor: 7.561

9.  Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis.

Authors:  Francisco J Rios; Zhi-Guo Zou; Adam P Harvey; Katie Y Harvey; Ryszard Nosalski; Panagiota Anyfanti; Livia L Camargo; Silvia Lacchini; Alexey G Ryazanov; Lillia Ryazanova; Sarah McGrath; Tomasz J Guzik; Carl S Goodyear; Augusto C Montezano; Rhian M Touyz
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

10.  Proteomics analysis of the matrisome from MC38 experimental mouse liver metastases.

Authors:  Arseniy E Yuzhalin; Su Yin Lim; Alex N Gordon-Weeks; Roman Fischer; Benedikt M Kessler; Dihua Yu; Ruth J Muschel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-09-23       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.